The immuno-oncology drug developer, which counts numerous pharmaceutical firms among its investors, has filed for a $100m offering in the US.

Germany-based cancer immunotherapy developer BioNTech has filed for a $100m initial public offering on the Nasdaq Global Select Market that would allow pharmaceutical companies Sanofi and Pfizer to exit. BioNTech, a spinout from Johannes Gutenberg University Mainz, is working on the development of individualised immunotherapies to treat cancer and potentially other diseases. Part of the…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.